{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:08:27Z","timestamp":1762045707220,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6799.15061"],"award-info":[{"award-number":["320.6799.15061"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["YXKC2020022"],"award-info":[{"award-number":["YXKC2020022"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study evaluated the association between adjuvant chemotherapy and the survival of cT1b-T2 patients with incidentally discovered positive lymph nodes (cN- but pN+) after esophagectomy for esophageal squamous cell carcinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>Esophageal cancer patients in whom positive lymph nodes were incidentally discovered after esophagectomy were enrolled in this retrospective cohort study. Patients were divided into the surgery alone and adjuvant chemotherapy groups. Propensity score matching (1:1) was used to minimize baseline differences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, data from 343 patients who were incidentally discovered to have positive lymph nodes after surgery were analyzed. Each group consisted of 107 patients, with no significant difference in the background information between the two groups. There was also no significant difference in the overall survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.227) or disease-free survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.210) between the groups in the matched overall study population. Notably, in subgroup analysis, The disease-free survival in the adjuvant chemotherapy group was significantly better than that in the operation group alone for patients with pathological stage T3 (<jats:italic>P<\/jats:italic>\u2009=\u20090.023). Multivariate analysis showed that male (ref: female, HR\u2009=\u20091.796, 95% CI, 1.013\u20133.183, <jats:italic>P<\/jats:italic>\u2009=\u20090.045) was a significant independent predictive factor for overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Adjuvant chemotherapy may improve survival for patients with cT1b-T2 but pathological T3 stage patients with incidentally discovered node-positive esophageal squamous cell carcinoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14472-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:49:47Z","timestamp":1751352587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Hai-Bo","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Kang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Ben","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14472_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Global Cancer. Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"14472_CR2","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMra1314530","volume":"371","author":"AK Rustgi","year":"2014","unstructured":"Rustgi AK, El-Serag HBE, Carcinoma. N Engl J Med. 2014;371:2499\u2013509.","journal-title":"N Engl J Med"},{"key":"14472_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"14472_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/cam4.3647","volume":"10","author":"F He","year":"2021","unstructured":"He F, Wang J, Liu L, Qin X, Wan Z, Li W, et al. Esophageal cancer: trends in incidence and mortality in China from 2005 to 2015. Cancer Med. 2021;10:1839\u201347.","journal-title":"Cancer Med"},{"key":"14472_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2015","unstructured":"Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal Cancer by histological subtype in 2012. Gut. 2015;64:381\u201387.","journal-title":"Gut"},{"key":"14472_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of Cancer burden worldwide and in china: A secondary analysis of the global Cancer statistics 2020. Chin Med J (Engl). 2021;134:783\u201391.","journal-title":"Chin Med J (Engl)"},{"key":"14472_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00419-3","volume":"18","author":"APG Thrift","year":"2021","unstructured":"Thrift APG. Burden and epidemiology of Barrett oesophagus and oesophageal Cancer. Nat Rev Gastroenterol Hepatol. 2021;18:432\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"14472_CR8","first-page":"e202185","volume":"13","author":"X Zhao","year":"2018","unstructured":"Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for Cancer of the esophagus or the gastroesophageal junction: A Meta-Analysis based on clinical trials. PLoS ONE. 2018;13:e202185.","journal-title":"PLoS ONE"},{"key":"14472_CR9","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.2147\/OTT.S145063","volume":"11","author":"HF Ma","year":"2018","unstructured":"Ma HF, Lv GX, Cai ZF, Zhang DH. Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: A Meta-Analysis. Onco Targets Ther. 2018;11:3441\u201347.","journal-title":"Onco Targets Ther"},{"key":"14472_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal Cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"14472_CR11","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","volume":"32","author":"C Mariette","year":"2014","unstructured":"Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416\u201322.","journal-title":"J Clin Oncol"},{"key":"14472_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","volume":"17","author":"JA Ajani","year":"2019","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:855\u201383.","journal-title":"J Natl Compr Canc Netw"},{"key":"14472_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.athoracsur.2017.01.092","volume":"104","author":"SJ Gao","year":"2017","unstructured":"Gao SJ, Park HS, Corso CD, Rutter CE, Kim AW, Johung KL. Role of adjuvant treatment in esophageal Cancer with incidental pathologic node positivity. Ann Thorac Surg. 2017;104:267\u201374.","journal-title":"Ann Thorac Surg"},{"key":"14472_CR14","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.1245\/s10434-021-09779-1","volume":"28","author":"Y Kubo","year":"2021","unstructured":"Kubo Y, Tanaka K, Yamasaki M, Yamashita K, Makino T, Saito T, et al. Influences of the Charlson comorbidity index and nutrition status on prognosis after esophageal Cancer surgery. Ann Surg Oncol. 2021;28:7173\u201382.","journal-title":"Ann Surg Oncol"},{"key":"14472_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/SLA.0b013e3181bdd5a8","volume":"250","author":"T Lerut","year":"2009","unstructured":"Lerut T, Moons J, Coosemans W, Van Raemdonck D, De Leyn P, Decaluwe H, et al. Postoperative complications after transthoracic esophagectomy for Cancer of the esophagus and gastroesophageal junction are correlated with early Cancer recurrence: role of systematic grading of complications using the modified clavien classification. Ann Surg. 2009;250:798\u2013807.","journal-title":"Ann Surg"},{"key":"14472_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3322\/caac.21399","volume":"67","author":"TW Rice","year":"2017","unstructured":"Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-Major changes in the American joint committee on Cancer eighth edition Cancer staging manual. CA Cancer J Clin. 2017;67:304\u201317.","journal-title":"CA Cancer J Clin"},{"key":"14472_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00000658-199602000-00003","volume":"223","author":"X Pouliquen","year":"1996","unstructured":"Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin. O 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French associations for surgical research. Ann Surg. 1996;223:127\u201333.","journal-title":"Ann Surg"},{"key":"14472_CR18","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1200\/JCO.2003.12.095","volume":"21","author":"N Ando","year":"2003","unstructured":"Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan clinical oncology group Study\u2013JCOG9204. J Clin Oncol. 2003;21:4592\u201396.","journal-title":"J Clin Oncol"},{"key":"14472_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0022-5223(97)70146-6","volume":"114","author":"N Ando","year":"1997","unstructured":"Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan clinical oncology group study. J Thorac Cardiovasc Surg. 1997;114:205\u201309.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"14472_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12032-016-0746-8","volume":"33","author":"RQ Qin","year":"2016","unstructured":"Qin RQ, Wen YS, Wang WP, Xi KX, Yu XY, Zhang LJ. The role of postoperative adjuvant chemotherapy for lymph Node-Positive esophageal squamous cell carcinoma: A propensity score matching analysis. Med Oncol. 2016;33:31.","journal-title":"Med Oncol"},{"key":"14472_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3892\/mco.2014.320","volume":"2","author":"T Hashiguchi","year":"2014","unstructured":"Hashiguchi T, Nasu M, Hashimoto T, Kuniyasu T, Inoue H, Sakai N, et al. Docetaxel, cisplatin and 5-Fluorouracil adjuvant chemotherapy following Three-Field lymph node dissection for stage II\/III N1, 2 esophageal Cancer. Mol Clin Oncol. 2014;2:719\u201324.","journal-title":"Mol Clin Oncol"},{"key":"14472_CR22","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/jso.23716","volume":"110","author":"X Lyu","year":"2014","unstructured":"Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K, et al. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?? J Surg Oncol. 2014;110:864\u201368.","journal-title":"J Surg Oncol"},{"key":"14472_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-Fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"14472_CR24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/1759-7714.14796","volume":"14","author":"YJ Jeon","year":"2023","unstructured":"Jeon YJ, Cho JH, Choi YS, Shim YM, Sun J-M, Kim HK. Adjuvant chemotherapy in node-positive patients after esophagectomy for esophageal squamous cell carcinoma. Thorac Cancer. 2023;14(6):624\u201335.","journal-title":"Thorac Cancer"},{"key":"14472_CR25","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/SLA.0000000000001557","volume":"264","author":"Y Akutsu","year":"2016","unstructured":"Akutsu Y, Kato K, Igaki H, Ito Y, Nozaki I, Daiko H, et al. The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: from the results of JCOG0502, a prospective multicenter study. Ann Surg. 2016;264:1009\u201315.","journal-title":"Ann Surg"},{"key":"14472_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.athoracsur.2013.03.093","volume":"96","author":"TD Crabtree","year":"2013","unstructured":"Crabtree TD, Kosinski AS, Puri V, Burfeind W, Bharat A, Patterson GA, et al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: A review of the society of thoracic surgeons database. Ann Thorac Surg. 2013;96:382\u201390.","journal-title":"Ann Thorac Surg"},{"key":"14472_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.2967\/jnumed.114.138974","volume":"55","author":"G Lee","year":"2014","unstructured":"Lee G, I H, Kim SJ, Jeong YJ, Kim IJ, Pak K, et al. Clinical implication of PET\/MR imaging in preoperative esophageal Cancer staging: comparison with PET\/CT, endoscopic ultrasonography, and CT. J Nucl Med. 2014;55:1242\u201347.","journal-title":"J Nucl Med"},{"key":"14472_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1148\/radiol.2021202857","volume":"299","author":"SL Lee","year":"2021","unstructured":"Lee SL, Yadav P, Starekova J, Christensen L, Chandereng T, Chappell R, et al. Diagnostic performance of MRI for esophageal carcinoma: A systematic review and Meta-Analysis. Radiology. 2021;299:583\u201394.","journal-title":"Radiology"},{"key":"14472_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/atm-20-1353","volume":"9","author":"D Lin","year":"2021","unstructured":"Lin D, Liu G, Jiang D, Yu Y, Wang H, Shi H, et al. The role of primary tumor SUVmax in the diagnosis of invasion depth: A step toward clinical T2N0 esophageal Cancer. Ann Transl Med. 2021;9:12.","journal-title":"Ann Transl Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14472-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14472-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14472-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:49:49Z","timestamp":1751352589000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14472-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14472"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14472-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Review Ethics Board of The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), and informed consent was obtained from all the participants(Institutional Review Board\u2013approved protocol number 2019082223, September 30, 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1060"}}